EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Exact Sciences's enterprise value is $14,839 Mil.
Exact Sciences's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was $59 Mil. Therefore, Exact Sciences's EV-to-EBITDA for today is 253.65.
The historical rank and industry rank for Exact Sciences's EV-to-EBITDA or its related term are showing as below:
EXAS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -6326.69 Med: -28.1 Max: 893.64
Current: 253.65
During the past 13 years, the highest EV-to-EBITDA of Exact Sciences was 893.64. The lowest was -6326.69. And the median was -28.10.
EXAS's EV-to-EBITDA is ranked worse than 99.1% of 111
companies
in the Medical Diagnostics & Research industry
Industry Median: 16.85
vs EXAS: 253.65
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Exact Sciences EV-to-EBITDA Historical Data
The historical data trend for Exact Sciences's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Exact Sciences's EV-to-EBITDA
For the Diagnostics & Research subindustry, Exact Sciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Exact Sciences's EV-to-EBITDA Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Exact Sciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Exact Sciences's EV-to-EBITDA falls into.
Exact Sciences EV-to-EBITDA Calculation
Exact Sciences's EV-to-EBITDA for today is calculated as:
Exact Sciences's current Enterprise Value is $14,839 Mil.
Exact Sciences's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $59 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Exact Sciences's PE Ratio (TTM) for today is calculated as:
Exact Sciences's share price for today is $68.93.
Exact Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.956.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Thank you for viewing the detailed overview of Exact Sciences's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, or MRD, colorectal cancer screening, and multicancer screening.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
EXAS has been successfully added to your 